Skip to main content

Table 3 Incremental cost-effectiveness ratio of the intervention and the sensitivity analysis

From: Cost-effectiveness and feasibility of conditional economic incentives and motivational interviewing to improve HIV health outcomes of adolescents living with HIV in Anambra State, Nigeria

   Cost of HIV care in the intervention arm (USD) Cost of HIV care in the control arm (USD) Cost difference (USD) Effectiveness (%) ICER ($US/ additional patient with undetectable viral load)
  Main model 338.70 172.68 166.02 0.117 1419
Sensitivity analysis Dolutegravir-based combination 338.70 172.68 166.02 0.089 1865
Changes in the cost of ART (±25% [L, U]) 317.00 & 360.4 145.35 & 200.00 171.65 & 160.40 0.117 1467 & 1371
Changes in the cost of non-ART (±25% [L, U]) 325.52 & 351.88 170.54 & 174.82 154.98 & 177.06 0.117 1325 & 1513
Changes in the CD4 and viral load tests costs (±25% [L, U]) 299.78 & 377.63 162.95 & 182.41 136.83 & 195.22 0.117 1169 & 1669
Triannual CD4 and viral load tests for the intervention arm 299.80 172.68 127.12 0.117 1086
Changes in viral load tests cost (±25% [L, U]) 305.37 & 372.03 164.36 & 181.01 141.01 & 191.02 0.117 1205 & 1632
Changes in the cost of ART, CD4, and viral load tests (±25% [L, U]) 278.08 & 399.32 135.62 & 209.74 142.46 & 189.58 0.117 1218 & 1620
  1. [L, U] lower and upper limit, ICER incremental cost-effectiveness ratio, ART antiretroviral therapy